Virtu Financial LLC Reduces Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Virtu Financial LLC reduced its stake in Humacyte, Inc. (NASDAQ:HUMA) by 61.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,102 shares of the company’s stock after selling 63,061 shares during the quarter. Virtu Financial LLC’s holdings in Humacyte were worth $218,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Humacyte in the second quarter worth $28,000. Concurrent Investment Advisors LLC acquired a new stake in Humacyte during the 3rd quarter worth about $75,000. Principal Financial Group Inc. purchased a new stake in Humacyte during the 2nd quarter valued at about $83,000. FORA Capital LLC purchased a new position in shares of Humacyte in the third quarter worth about $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte during the second quarter worth about $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Humacyte Trading Down 6.8 %

Shares of NASDAQ:HUMA opened at $3.54 on Thursday. The firm has a market capitalization of $445.54 million, a price-to-earnings ratio of -2.64 and a beta of 1.38. The business’s 50 day moving average price is $4.89 and its 200-day moving average price is $5.88. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte, Inc. has a 1 year low of $2.48 and a 1 year high of $9.97.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Humacyte in a report on Wednesday, November 13th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Finally, TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $13.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.